95 related articles for article (PubMed ID: 23043422)
1. Hepatic sinusoidal obstruction syndrome reduces the effect of oxaliplatin in colorectal liver metastases.
Robinson SM; White SA
Histopathology; 2012 Dec; 61(6):1247-8. PubMed ID: 23043422
[No Abstract] [Full Text] [Related]
2. Hepatic sinusoidal obstruction syndrome (SOS) reduces the effect of oxaliplatin in colorectal liver metastases.
Vreuls CP; Van Den Broek MA; Winstanley A; Koek GH; Wisse E; Dejong CH; Olde Damink SW; Bosman FT; Driessen A
Histopathology; 2012 Aug; 61(2):314-8. PubMed ID: 22571348
[TBL] [Abstract][Full Text] [Related]
3. Hepatic veno-occlusive disease after neoadjuvant treatment of colorectal liver metastases with oxaliplatin: a lesson of the month.
Schouten van der Velden AP; Punt CJ; Van Krieken JH; Derleyn VA; Ruers TJ
Eur J Surg Oncol; 2008 Mar; 34(3):353-5. PubMed ID: 17207961
[TBL] [Abstract][Full Text] [Related]
4. Predicting high grade lesions of sinusoidal obstruction syndrome related to oxaliplatin-based chemotherapy for colorectal liver metastases: correlation with post-hepatectomy outcome.
Soubrane O; Brouquet A; Zalinski S; Terris B; Brézault C; Mallet V; Goldwasser F; Scatton O
Ann Surg; 2010 Mar; 251(3):454-60. PubMed ID: 20160638
[TBL] [Abstract][Full Text] [Related]
5. Sinusoidal obstruction syndrome after oxaliplatin-based chemotherapy.
Seo AN; Kim H
Clin Mol Hepatol; 2014 Mar; 20(1):81-4. PubMed ID: 24757663
[No Abstract] [Full Text] [Related]
6. Sinusoidal obstruction syndrome is a major feature of hepatic lesions associated with oxaliplatin neoadjuvant chemotherapy for liver colorectal metastases.
Rubbia-Brandt L; Mentha G; Terris B
J Am Coll Surg; 2006 Jan; 202(1):199-200. PubMed ID: 16377516
[No Abstract] [Full Text] [Related]
7. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer.
Rubbia-Brandt L; Audard V; Sartoretti P; Roth AD; Brezault C; Le Charpentier M; Dousset B; Morel P; Soubrane O; Chaussade S; Mentha G; Terris B
Ann Oncol; 2004 Mar; 15(3):460-6. PubMed ID: 14998849
[TBL] [Abstract][Full Text] [Related]
8. Hepatic Parenchymal Heterogeneity as a Marker for Oxaliplatin-Induced Sinusoidal Obstruction Syndrome: Correlation With Treatment Response of Colorectal Cancer Liver Metastases.
Han NY; Park BJ; Yang KS; Kim MJ; Sung DJ; Sim KC; Cho SB
AJR Am J Roentgenol; 2017 Nov; 209(5):1039-1045. PubMed ID: 28813196
[TBL] [Abstract][Full Text] [Related]
9. Splenic volume may be a useful indicator of the protective effect of bevacizumab against oxaliplatin-induced hepatic sinusoidal obstruction syndrome.
Imai K; Emi Y; Iyama KI; Beppu T; Ogata Y; Kakeji Y; Samura H; Oki E; Akagi Y; Maehara Y; Baba H;
Eur J Surg Oncol; 2014 May; 40(5):559-566. PubMed ID: 24388740
[TBL] [Abstract][Full Text] [Related]
10. Hepatic complications following preoperative chemotherapy with oxaliplatin or irinotecan for hepatic colorectal metastases.
Morris-Stiff G; Tan YM; Vauthey JN
Eur J Surg Oncol; 2008 Jun; 34(6):609-14. PubMed ID: 17764887
[TBL] [Abstract][Full Text] [Related]
11. Severe hepatic sinusoidal obstruction and oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer: a real entity?
Sebagh M; Plasse M; Lévi F; Adam R
Ann Oncol; 2005 Feb; 16(2):331; author reply 332-3. PubMed ID: 15668292
[No Abstract] [Full Text] [Related]
12. Sinusoidal obstruction syndrome (SOS): A light and electron microscopy study in human liver.
Vreuls CP; Driessen A; Olde Damink SW; Koek GH; Duimel H; van den Broek MA; Dejong CH; Braet F; Wisse E
Micron; 2016 May; 84():17-22. PubMed ID: 26914502
[TBL] [Abstract][Full Text] [Related]
13. Hepatic regeneration is decreased in a rat model of sinusoidal obstruction syndrome.
Schiffer E; Frossard JL; Rubbia-Brandt L; Mentha G; Pastor CM
J Surg Oncol; 2009 Jun; 99(7):439-46. PubMed ID: 19353590
[TBL] [Abstract][Full Text] [Related]
14. Liver injury due to chemotherapy-induced sinusoidal obstruction syndrome is associated with sinusoidal capillarization.
Narita M; Oussoultzoglou E; Chenard MP; Fuchshuber P; Rather M; Rosso E; Addeo P; Jaeck D; Bachellier P
Ann Surg Oncol; 2012 Jul; 19(7):2230-7. PubMed ID: 22402811
[TBL] [Abstract][Full Text] [Related]
15. A phase I study of hyperthermic isolated hepatic perfusion with oxaliplatin in the treatment of unresectable liver metastases from colorectal cancer.
Zeh HJ; Brown CK; Holtzman MP; Egorin MJ; Holleran JL; Potter DM; Bartlett DL
Ann Surg Oncol; 2009 Feb; 16(2):385-94. PubMed ID: 19034580
[TBL] [Abstract][Full Text] [Related]
16. Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis.
Rubbia-Brandt L; Lauwers GY; Wang H; Majno PE; Tanabe K; Zhu AX; Brezault C; Soubrane O; Abdalla EK; Vauthey JN; Mentha G; Terris B
Histopathology; 2010 Mar; 56(4):430-9. PubMed ID: 20459550
[TBL] [Abstract][Full Text] [Related]
17. Reduction of nonresectable liver metastasis from colorectal cancer after oxaliplatin chemotherapy.
Bismuth H; Adam R
Semin Oncol; 1998 Apr; 25(2 Suppl 5):40-6. PubMed ID: 9609107
[TBL] [Abstract][Full Text] [Related]
18. Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury.
Overman MJ; Maru DM; Charnsangavej C; Loyer EM; Wang H; Pathak P; Eng C; Hoff PM; Vauthey JN; Wolff RA; Kopetz S
J Clin Oncol; 2010 May; 28(15):2549-55. PubMed ID: 20406923
[TBL] [Abstract][Full Text] [Related]
19. Re: Preoperative chemotherapy and the outcome of liver resection for colorectal metastases.
Hewes J
World J Surg; 2007 Sep; 31(9):1902. PubMed ID: 17487524
[No Abstract] [Full Text] [Related]
20. Identification of molecular pathways involved in oxaliplatin-associated sinusoidal dilatation.
Agostini J; Benoist S; Seman M; Julié C; Imbeaud S; Letourneur F; Cagnard N; Rougier P; Brouquet A; Zucman-Rossi J; Laurent-Puig P
J Hepatol; 2012 Apr; 56(4):869-76. PubMed ID: 22200551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
